Andrés Vargas1. 1. Department of Radiation Oncology, Instituto de Radiomedicina (IRAM), Ave. Américo Vespucio Norte 1314, 7630370. Santiago, Chile.
Abstract
INTRODUCTION: Single fraction radiotherapy (SFR) is effective in palliation of symptoms related to advanced cancer. Despite this, several studies have shown that the trend towards multiple fraction treatment (MFR) is largely maintained. Even in patients with limited life expectancy, SFR is significantly underutilized in current practice. CASES DESCRIPTION: Four patients diagnosed with advanced cancer who developed soft tissue lesions were treated with SFR due to frailty and/or a poor performance status. CONCLUSION: Despite the effectiveness of SFR is well-established in BM, its use in symptoms caused by soft tissue lesions have been underreported. SFR could be a good option for providing palliation in some patients, particularly in those who are frail or have a poor performance status.
INTRODUCTION: Single fraction radiotherapy (SFR) is effective in palliation of symptoms related to advanced cancer. Despite this, several studies have shown that the trend towards multiple fraction treatment (MFR) is largely maintained. Even in patients with limited life expectancy, SFR is significantly underutilized in current practice. CASES DESCRIPTION: Four patients diagnosed with advanced cancer who developed soft tissue lesions were treated with SFR due to frailty and/or a poor performance status. CONCLUSION: Despite the effectiveness of SFR is well-established in BM, its use in symptoms caused by soft tissue lesions have been underreported. SFR could be a good option for providing palliation in some patients, particularly in those who are frail or have a poor performance status.
Authors: Sonia Skamene; Isha Agarwal; Maggie Makar; Monica Krishnan; Alex Spektor; Lauren Hertan; Kent W Mouw; Allison Taylor; Sarah Noveroske Philbrick; Tracy Balboni Journal: Ann Palliat Med Date: 2017-11-30
Authors: E Steenland; J W Leer; H van Houwelingen; W J Post; W B van den Hout; J Kievit; H de Haes; H Martijn; B Oei; E Vonk; E van der Steen-Banasik; R G Wiggenraad; J Hoogenhout; C Wárlám-Rodenhuis; G van Tienhoven; R Wanders; J Pomp; M van Reijn; I van Mierlo; E Rutten; J Leer; T van Mierlo Journal: Radiother Oncol Date: 1999-08 Impact factor: 6.280
Authors: William F Hartsell; Charles B Scott; Deborah Watkins Bruner; Charles W Scarantino; Robert A Ivker; Mack Roach; John H Suh; William F Demas; Benjamin Movsas; Ivy A Petersen; Andre A Konski; Charles S Cleeland; Nora A Janjan; Michelle DeSilvio Journal: J Natl Cancer Inst Date: 2005-06-01 Impact factor: 13.506
Authors: Lucia Gutiérrez Bayard; María Del Carmen Salas Buzón; Esther Angulo Paín; Lourdes de Ingunza Barón Journal: Rep Pract Oncol Radiother Date: 2014-05-06
Authors: A N Petrushevski; G S Gabriel; T P Hanna; S Allen; R W Allison; M B Barton Journal: Clin Oncol (R Coll Radiol) Date: 2014-12-17 Impact factor: 4.126
Authors: Susan Y Wu; Lisa Singer; Lauren Boreta; Michael A Garcia; Shannon E Fogh; Steve E Braunstein Journal: BMC Palliat Care Date: 2019-03-23 Impact factor: 3.234
Authors: Paul M Cheon; Erin Wong; Nemica Thavarajah; Kristopher Dennis; Stephen Lutz; Liang Zeng; Edward Chow Journal: J Bone Oncol Date: 2015-01-23 Impact factor: 4.072